Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  title={Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.},
  author={B. Druker and F. Guilhot and S. O'Brien and I. Gathmann and H. Kantarjian and N. Gattermann and M. Deininger and R. Silver and J. Goldman and R. Stone and F. Cervantes and A. Hochhaus and B. Powell and J. Gabrilove and Philippe Rousselot and J. Reiffers and J. Cornelissen and Timothy W. Hughes and H. Agis and T. Fischer and G. Verhoef and J. Shepherd and G. Saglio and A. Gratwohl and J. Nielsen and J. Radich and B. Simonsson and K. Taylor and M. Baccarani and Charlene So and L. Letvak and R. Larson},
  journal={The New England journal of medicine},
  volume={355 23},
  • B. Druker, F. Guilhot, +29 authors R. Larson
  • Published 2006
  • Medicine
  • The New England journal of medicine
  • BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and… CONTINUE READING
    3,106 Citations

    Paper Mentions

    Observational Clinical Trial
    This study is an extension study (prospective observational study) of 'IDEAL' study (A Study to Evaluate Efficacy and Safety of Imatinib (Glinib) 600mg/day depending on Early Molecular… Expand
    ConditionsLeukemia, Myelogenous, Chronic, BCR-ABL Positive
    Interventional Clinical Trial
    The results of the International Randomized Study of Interferon and STI571 (IRIS) trial indicate that in patients with chronic phase CML treated with first line imatinib… Expand
    ConditionsChronic Myelogenous Leukemia
    Interventional Clinical Trial
    DANIN study is a randomized, phase 3 clinical trial comparing 'head to head' Nilotinib versus Dasatinib as upfront therapy for patient with chronic myeloid leukemia. The efficacy of both… Expand
    ConditionsChronic Myeloid Leukemia - Chronic Phase
    Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
    • 440
    • PDF
    Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
    • 471
    • PDF
    Imatinib Mesylate Therapy in Patients of Chronic Myeloid Leukemia with Philadelphia Chromosome Positive: An Experience from Eastern India
    • 9
    • Highly Influenced
    Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    • 533


    Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
    • 1,988
    Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    • 1,548
    • PDF
    Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
    • 1,213
    • PDF
    Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    • 4,762
    • PDF